Literature DB >> 21988191

Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays.

S A Baylis1, L Ma, D J Padley, A B Heath, M W Yu.   

Abstract

BACKGROUND AND OBJECTIVES: The aim of the collaborative study was to evaluate a panel of plasma samples containing different genotypes of parvovirus B19 (B19V) for use in nucleic acid amplification technology (NAT)-based assays.
MATERIALS AND METHODS: The panel of samples [Center for Biologics Evaluation and Research Parvovirus B19 Genotype Panel 1; National Institute for Biological Standards and Control (NIBSC) code number 09/110] comprises four different members, i.e. Member 1, Member 2, Member 3, and Member 4 (M1-M4); these represent genotypes 1, 2, 3a B19V, and a negative plasma control, respectively. Thirty-five laboratories from 13 different countries participated in the study. Participants assayed the panel members concurrently with the 2nd World Health Organization (WHO) International Standard for B19V DNA (NIBSC code 99/802) on four separate occasions.
RESULTS: A total of 44 sets of data were returned, 34 from quantitative assays and 10 from qualitative assays. The majority of assays used were in-house and based on real-time PCR. The results showed that all three genotypes were detected consistently by the majority of participants, although a small number of assays detected genotypes 2 and 3 less efficiently, or not at all. Real-time stability studies have indicated that the panel of B19V samples is stable under normal conditions of storage, i.e. ≤-70°C.
CONCLUSIONS: The four-member panel is intended for use in evaluating the ability of NAT assays to detect different B19V genotypes (M1-M3). Based on the results of the collaborative study, the panel was established as the 1st WHO International Reference Panel for parvovirus B19 genotypes.
© 2011 The Author(s). Vox Sanguinis © 2011 International Society of Blood Transfusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21988191     DOI: 10.1111/j.1423-0410.2011.01541.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  7 in total

1.  Characterization of Markers of the Progression of Human Parvovirus B19 Infection in Virus DNA-Positive Plasma Samples.

Authors:  Xavier Bonjoch; Francesc Obispo; Cristina Alemany; Ana Pacha; Esteban Rodríguez; Dolors Xairó
Journal:  Transfus Med Hemother       Date:  2015-04-23       Impact factor: 3.747

Review 2.  Standardization of Nucleic Acid Tests: the Approach of the World Health Organization.

Authors:  S A Baylis; P Wallace; E McCulloch; H G M Niesters; C M Nübling
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

3.  Keeping pace with parvovirus B19 genetic variability: a multiplex genotype-specific quantitative PCR assay.

Authors:  Francesca Bonvicini; Elisabetta Manaresi; Gloria Bua; Simona Venturoli; Giorgio Gallinella
Journal:  J Clin Microbiol       Date:  2013-09-04       Impact factor: 5.948

Review 4.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2013-11-20       Impact factor: 5.948

Review 6.  Standardization of NAT for Blood-Borne Pathogens.

Authors:  Sally A Baylis; Michael Chudy; C Micha Nübling
Journal:  Transfus Med Hemother       Date:  2015-07-01       Impact factor: 3.747

7.  Genome sequences of parvovirus b19 reference strains.

Authors:  Jan-Hendrik Trösemeier; Annika Branting; Vladimir V Lukashov; Johannes Blümel; Sally A Baylis
Journal:  Genome Announc       Date:  2014-10-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.